Stock DNA
Pharmaceuticals & Biotechnology
USD 1,957 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.35
-999,999.00%
0.76
Revenue and Profits:
Net Sales:
44 Million
(Quarterly Results - Dec 2025)
Net Profit:
-99 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-54.0%
0%
-54.0%
6 Months
25.67%
0%
25.67%
1 Year
5.65%
0%
5.65%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
GRAIL, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
171.70%
EBIT Growth (5y)
-164.01%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
93.34%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.43
EV to EBIT
-4.64
EV to EBITDA
-6.32
EV to Capital Employed
1.58
EV to Sales
20.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-34.00%
ROE (Latest)
-17.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 86 Schemes (27.01%)
Foreign Institutions
Held by 222 Foreign Institutions (10.29%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
43.60
36.20
20.44%
Operating Profit (PBDIT) excl Other Income
-85.50
-86.30
0.93%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-99.20
-89.00
-11.46%
Operating Profit Margin (Excl OI)
-2,853.70%
-3,461.70%
60.80%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 20.44% vs 1.97% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -11.46% vs 21.93% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
147.20
125.60
17.20%
Operating Profit (PBDIT) excl Other Income
-377.80
-569.70
33.68%
Interest
0.00
0.00
Exceptional Items
-28.00
-1,461.40
98.08%
Consolidate Net Profit
-408.40
-2,027.00
79.85%
Operating Profit Margin (Excl OI)
-3,629.50%
-5,794.40%
216.49%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 17.20% vs 34.91% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 79.85% vs -38.30% in Dec 2024






